# Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

> **NCT02279602** · PHASE2 · COMPLETED · sponsor: **Mateon Therapeutics** · enrollment: 7 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** fosbretabulin

## Key facts

- **NCT ID:** NCT02279602
- **Lead sponsor:** Mateon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2018-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02279602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02279602, "Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02279602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*